1,125 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anakinra Non-Small Cell Lung Carcinoma	Thomas Marron	P1/2	CC (47)
ap203 Non-Small Cell Lung Carcinoma	AP Biosciences Inc.	P1/2	CC (47)
Bafisontamab Non-Small Cell Lung Carcinoma	Shanghai EpimAb Biotherapeutics Co., Ltd.	P1/2	CC (47)
Bms-936558-01 Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P1/2	CC (47)
Camu Camu Non-Small Cell Lung Carcinoma	Centre hospitalier de l'Université de Montréal (CHUM)	P1	CC (47)
Efineptakin Alfa Non-Small Cell Lung Carcinoma	NeoImmuneTech	P2	CC (47)
Eras-007 Non-Small Cell Lung Carcinoma	Erasca, Inc.	P1	CC (47)
Eras-601 Non-Small Cell Lung Carcinoma	Erasca, Inc.	P1	CC (47)
iap0971 Non-Small Cell Lung Carcinoma	SUNHO（China）BioPharmaceutical CO., Ltd.	P1/2	CC (47)
Idp-001 Non-Small Cell Lung Carcinoma	InduPro, Inc.	P1/2	CC (47)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P1/2	CC (47)
jyp0015 Non-Small Cell Lung Carcinoma	Guangzhou JOYO Pharma Co., Ltd	P2	CC (47)
kb707 Non-Small Cell Lung Carcinoma	Krystal Biotech, Inc.	P1/2	CC (47)
Oncolytic Virus Rp1 Non-Small Cell Lung Carcinoma	Replimune, Inc.	P2	CC (47)
prt3645 Non-Small Cell Lung Carcinoma	Prelude Therapeutics	P1	CC (47)
Shr-A2102 For Non-Small Cell Lung Carcinoma	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CC (47)
Sodium Nucleinate Non-Small Cell Lung Carcinoma	MIPO Clinic	P1	CC (47)
Vmd-102 Non-Small Cell Lung Carcinoma	VM Discovery, Inc.	P1/2	CC (47)
XP-102 Non-Small Cell Lung Carcinoma	Xynomic Pharmaceuticals, Inc.	P1/2	CC (47)
Xzp-5955 Tablets Non-Small Cell Lung Carcinoma	Xuanzhu Biopharmaceutical Co., Ltd.	P1/2	CC (47)
Anti-Pd-L1 Monoclonal Antibody Ck-301 Non-Small Cell Lung Carcinoma	Checkpoint Therapeutics, Inc.	P3	CC (46)
Bgb-15025 Non-Small Cell Lung Carcinoma	BeiGene	P2	CC (46)
Cetrelimab Non-Small Cell Lung Carcinoma	Ankyra Therapeutics, Inc	P1/2	CC (46)
dzd6008 Non-Small Cell Lung Carcinoma	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	P1/2	CC (46)
GB491 Non-Small Cell Lung Carcinoma	Genor Biopharma Co., Ltd.	P1	CC (46)
Hmbd-002 Non-Small Cell Lung Carcinoma	Hummingbird Bioscience	P1	CC (46)
Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P2	CC (46)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tnfrsf4 (Tumor Necrosis Factor Receptor (Tnfr) Superfamily Member 4, Ox40, Cd134)], Humanized Monoclonal Antibody Non-Small Cell Lung Carcinoma	BeiGene	P2	CC (46)
Immunoglobulin G4 [234-Proline], Anti-(Human Protein Garp-Transforming Growth Factor ?1 Complex) (Human Monoclonal Abbv-151 ?4-Chain), Disulfide With Human Monoclonal Abbv-151 ?-Chain, Dimer Non-Small Cell Lung Carcinoma	AbbVie	P2/3	CC (46)
Nazartinib Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P2	CC (46)
Rmc-9805 Non-Small Cell Lung Carcinoma	Tango Therapeutics, Inc.	P1/2	CC (46)
Roginolisib Non-Small Cell Lung Carcinoma	iOnctura	P1/2	CC (46)
Saruparib Non-Small Cell Lung Carcinoma	University of Leeds	P1/2	CC (46)
Syhx2011 Non-Small Cell Lung Carcinoma	Shanghai Chest Hospital	P2/3	CC (46)
Temuterkib Non-Small Cell Lung Carcinoma	The Netherlands Cancer Institute	P1	CC (46)
Thymosin Alpha 1 Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	CC (46)
Zanzalintinib Non-Small Cell Lung Carcinoma	Exelixis	P1/2	CC (46)
Zilongjin Non-Small Cell Lung Carcinoma	Kong Fanming	P2/3	CC (46)
177lu-betabart Non-Small Cell Lung Carcinoma	Radiopharm Theranostics, Ltd	P1/2	CC (45)
Adebelimumab Non-Small Cell Lung Carcinoma	Jiangsu Province Nanjing Brain Hospital	P2	CC (45)
Akkermansia Muciniphila Non-Small Cell Lung Carcinoma	EverImmune	P2	CC (45)
Alirocumab Non-Small Cell Lung Carcinoma	Duke University	P2	CC (45)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Non-Small Cell Lung Carcinoma	Anhui Provincial Cancer Hospital	P2	CC (45)
bh-30643 Non-Small Cell Lung Carcinoma	BlossomHill Therapeutics	P1/2	CC (45)
bi 907828 Non-Small Cell Lung Carcinoma	Institut Bergonié	P2	CC (45)
Bms 986315 Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P2	CC (45)
Bozitinib Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	CC (45)
Brivestobart Non-Small Cell Lung Carcinoma	Guangzhou Gloria Biosciences Co., Ltd.	P1/2	CC (45)
Chlorhexidine Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CC (45)
Cis-Dpi Non-Small Cell Lung Carcinoma	Inhatarget Therapeutics	P1/2	CC (45)

Showing 451 to 500 of 1,125 assets

PreviousPage 10 of 23Next